TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Roth Mkm

Roth Mkm began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm set a "buy" rating and a $11.00 price target on the stock. Roth Mkm's target price would suggest a potential upside of 148.31% from the company's current price.

Other research analysts have also issued reports about the company. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an "outperform" rating and a $12.50 target price on the stock. Oppenheimer began coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an "outperform" rating and a $10.00 price objective for the company. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $12.25.

TriSalus Life Sciences Trading Up 4.7 %

Shares of TLSI traded up $0.20 during midday trading on Monday, reaching $4.43. The stock had a trading volume of 23,976 shares, compared to its average volume of 38,239. The firm has a market cap of $135.07 million, a PE ratio of -1.69 and a beta of 0.49. The firm has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $5.94. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $7.36 million during the quarter. As a group, research analysts forecast that TriSalus Life Sciences will post -1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CEO Mary T. Szela bought 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $5.20 per share, with a total value of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 32.80% of the company's stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently made changes to their positions in the stock. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences in the 2nd quarter valued at $1,184,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the second quarter worth $240,000. Finally, Duquesne Family Office LLC raised its stake in TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after purchasing an additional 110,966 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.